Clinical management of patients with drug-induced liver injury (DILI). [PDF]
United European Gastroenterol J, 2021 AbstractDrug‐induced liver injury (DILI) should be considered in all patients with recent elevation of liver tests without obvious etiology and normal hepatobiliary imaging. There is currently no biomarker that is helpful in diagnosis which relies on clinical and laboratory findings.
Björnsson ES.
europepmc +6 more sources
Drug-induced liver injury (DILI) - mechanisms and diagnostic [PDF]
Farmacja Polska, 2022 The drug-induced liver injury (DILI) is one of the leading causes of the liver disease in developed countries. These injuries may be the result of constant drug hepatotoxicity or idiosyncrasy associated with the drug or its metabolite.
Marta Małysz +3 more
doaj +3 more sources
The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment. [PDF]
Metabolites, 2022 Drug-induced liver injury (DILI) is one of the most frequent adverse clinical reactions and a relevant cause of morbidity and mortality. Hepatotoxicity is among the major reasons for drug withdrawal during post-market and late development stages, representing a major concern to the pharmaceutical industry.
Moreno-Torres M, Quintás G, Castell JV.
europepmc +8 more sources
Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes. [PDF]
Arch Toxicol, 2021 AbstractDrug-induced liver injury (DILI) is an adverse toxic hepatic clinical reaction associated to the administration of a drug that can occur both at early clinical stages of drug development, as well after normal clinical usage of approved drugs. Because of its unpredictability and clinical relevance, it is of medical concern. Three DILI phenotypes
Quintás G +5 more
europepmc +7 more sources
Comment: Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment. [PDF]
Ann Pharmacother, 2021 Danjuma M +4 more
europepmc +6 more sources
A new framework for advancing in drug‐induced liver injury research. The Prospective European
Liver International, 2022 Background & AimsNo multi-national prospective study of drug-induced liver injury (DILI) has originated from Europe. The design of a prospective European DILI registry, clinical features and short-term outcomes of the cases and controls is reported ...
Einar S. Björnsson +13 more
core +14 more sources
Role of Corticosteroids in Drug-Induced Liver Injury. A Systematic Review [PDF]
Frontiers in Pharmacology, 2022 Introduction: Apart from cessation of the implicated agent leading to drug-induced liver injury (DILI), there is no standard therapy for DILI. Corticosteroids have been used in DILI, although their efficacy is unclear.
Einar S. Björnsson +4 more
doaj +4 more sources
Comparing Machine Learning Algorithms for Predicting Drug-Induced Liver Injury (DILI). [PDF]
Mol Pharm, 2020 Drug-induced liver injury (DILI) is one the most unpredictable adverse reactions to xenobiotics in humans and the leading cause of postmarketing withdrawals of approved drugs. To date, these drugs have been collated by the FDA to form the DILIRank database, which classifies DILI severity and potential.
Minerali E +4 more
europepmc +6 more sources
Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury via mitochondrial or other mechanisms [PDF]
Acta Pharmaceutica Sinica B, 2021 Drug-induced liver injury (DILI) is a leading reason for preclinical safety attrition and post-market drug withdrawals. Drug-induced mitochondrial toxicity has been shown to play an essential role in various forms of DILI, especially in idiosyncratic ...
Payal Rana +3 more
doaj +3 more sources
A case report of a drug-induced liver injury (DILI) caused by multiple antidepressants with causality established by the updated Roussel Uclaf causality assessment method (RUCAM) and in vitro testing. [PDF]
Clin Case Rep, 2020 González-Muñoz M +8 more
europepmc +3 more sources